WO2007077465A3 - Treatment of hiv - Google Patents

Treatment of hiv Download PDF

Info

Publication number
WO2007077465A3
WO2007077465A3 PCT/GB2007/050006 GB2007050006W WO2007077465A3 WO 2007077465 A3 WO2007077465 A3 WO 2007077465A3 GB 2007050006 W GB2007050006 W GB 2007050006W WO 2007077465 A3 WO2007077465 A3 WO 2007077465A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
treatment
peptides
proopiomelanocortin
pomc
Prior art date
Application number
PCT/GB2007/050006
Other languages
French (fr)
Other versions
WO2007077465A2 (en
Inventor
Deirdre Mcintosh
Original Assignee
Aimsco Ltd
Deirdre Mcintosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2008008768A priority Critical patent/MX2008008768A/en
Priority to AP2008004560A priority patent/AP2913A/en
Priority to JP2008549065A priority patent/JP5180095B2/en
Priority to EP07700413A priority patent/EP1968624A2/en
Priority to BRPI0706311-3A priority patent/BRPI0706311A2/en
Priority to CA002635562A priority patent/CA2635562A1/en
Priority to NZ569604A priority patent/NZ569604A/en
Priority to AU2007203991A priority patent/AU2007203991B2/en
Application filed by Aimsco Ltd, Deirdre Mcintosh filed Critical Aimsco Ltd
Priority to KR1020147023081A priority patent/KR20140114443A/en
Priority to US12/087,442 priority patent/US20090291060A1/en
Priority to EA200870158A priority patent/EA015924B1/en
Publication of WO2007077465A2 publication Critical patent/WO2007077465A2/en
Publication of WO2007077465A3 publication Critical patent/WO2007077465A3/en
Priority to IL192618A priority patent/IL192618A/en
Priority to US13/450,597 priority patent/US20120208745A1/en
Priority to US13/693,174 priority patent/US20130210710A1/en
Priority to US14/080,693 priority patent/US20140072530A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.
PCT/GB2007/050006 2006-01-06 2007-01-05 Treatment of hiv WO2007077465A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020147023081A KR20140114443A (en) 2006-01-06 2007-01-05 Treatment of HIV
AP2008004560A AP2913A (en) 2006-01-06 2007-01-05 Treatment of HIV
US12/087,442 US20090291060A1 (en) 2006-01-06 2007-01-05 Treatment of HIV
BRPI0706311-3A BRPI0706311A2 (en) 2006-01-06 2007-01-05 hiv treatment method, and, use of a peptide
CA002635562A CA2635562A1 (en) 2006-01-06 2007-01-05 Treatment of hiv using proopiomelanocortin (pomc) and corticotropin releasing factor (crf) and their products
NZ569604A NZ569604A (en) 2006-01-06 2007-01-05 Treatment of HIV comprising administering a corticotropin releasing factor (CRF) peptide
AU2007203991A AU2007203991B2 (en) 2006-01-06 2007-01-05 Treatment of HIV
MX2008008768A MX2008008768A (en) 2006-01-06 2007-01-05 Treatment of hiv.
JP2008549065A JP5180095B2 (en) 2006-01-06 2007-01-05 HIV treatment
EP07700413A EP1968624A2 (en) 2006-01-06 2007-01-05 Treatment of hiv
EA200870158A EA015924B1 (en) 2006-01-06 2007-01-05 Treatment of hiv
IL192618A IL192618A (en) 2006-01-06 2008-07-03 Corticotropin releasing factor (crf) and proopiomelanocortin (pomc) for use in treatment of hiv
US13/450,597 US20120208745A1 (en) 2006-01-06 2012-04-19 Treatment of hiv
US13/693,174 US20130210710A1 (en) 2006-01-06 2012-12-04 Treatment of hiv
US14/080,693 US20140072530A1 (en) 2006-01-06 2013-11-14 Treatment of hiv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0600202.6 2006-01-06
GBGB0600202.6A GB0600202D0 (en) 2006-01-06 2006-01-06 Treatment of HIV

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/087,442 A-371-Of-International US20090291060A1 (en) 2006-01-06 2007-01-05 Treatment of HIV
US13/450,597 Continuation US20120208745A1 (en) 2006-01-06 2012-04-19 Treatment of hiv

Publications (2)

Publication Number Publication Date
WO2007077465A2 WO2007077465A2 (en) 2007-07-12
WO2007077465A3 true WO2007077465A3 (en) 2007-11-08

Family

ID=35911459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050006 WO2007077465A2 (en) 2006-01-06 2007-01-05 Treatment of hiv

Country Status (16)

Country Link
US (4) US20090291060A1 (en)
EP (1) EP1968624A2 (en)
JP (1) JP5180095B2 (en)
KR (2) KR20080098488A (en)
CN (1) CN101394862A (en)
AP (1) AP2913A (en)
AU (1) AU2007203991B2 (en)
BR (1) BRPI0706311A2 (en)
CA (1) CA2635562A1 (en)
EA (1) EA015924B1 (en)
GB (1) GB0600202D0 (en)
IL (1) IL192618A (en)
MX (1) MX2008008768A (en)
NZ (1) NZ569604A (en)
WO (1) WO2007077465A2 (en)
ZA (1) ZA200806505B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
WO2010098079A1 (en) * 2009-02-24 2010-09-02 学校法人金沢医科大学 Method for denucleating nucleated erythrocyte, and denucleation inducer
EP2701728B1 (en) 2012-06-25 2015-05-06 Aimsco Limited Formulation comprising crh and alpha-2-macroglobulin
US20130344102A1 (en) * 2012-06-25 2013-12-26 Aimsco Limited Formulation
GB201617175D0 (en) * 2016-10-10 2016-11-23 Iconic Intellectual Property Limited Assay
US11285192B2 (en) * 2019-03-13 2022-03-29 Adamis Pharmaceuticals Corporation Formulation including a combination of beta-endorphin and adrenocorticotropic hormone
SG11202109652TA (en) * 2019-03-13 2021-10-28 Adamis Pharmaceuticals Corp FORMULATION INCLUDING A COMBINATION OF ß-ENDORPHIN AND ADRENOCORTICOTROPIC HORMONE

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
WO1991001997A1 (en) * 1989-07-28 1991-02-21 The Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
WO2001047983A1 (en) * 1999-12-24 2001-07-05 Biowindow Gene Development Inc. Shanghai A novel polypeptide - corticotrophin releasing factor 13 and a polynucleotide encoding the same
WO2002051867A1 (en) * 2000-12-26 2002-07-04 Biowindow Gene Development Inc. Shanghai A novel polypeptide-corticotropin releasing factor 8.8 and the polynucleotide encoding said polypeptide
WO2002067996A2 (en) * 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Beta-endorphin/crf gene therapy for locally combating pain
WO2003004049A2 (en) * 2001-07-02 2003-01-16 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2006021814A2 (en) * 2004-07-08 2006-03-02 Aimsco Limited Medicament
WO2006117573A1 (en) * 2005-05-04 2006-11-09 Aimsco Limited Combination therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275696A1 (en) * 2000-07-21 2002-02-05 Ice Biologics Limited Therapeutic agent
AU2003202093B2 (en) * 2001-07-02 2010-05-13 Aimsco Limited Treatment of MS with goat serum

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
WO1991001997A1 (en) * 1989-07-28 1991-02-21 The Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
WO2001047983A1 (en) * 1999-12-24 2001-07-05 Biowindow Gene Development Inc. Shanghai A novel polypeptide - corticotrophin releasing factor 13 and a polynucleotide encoding the same
WO2002051867A1 (en) * 2000-12-26 2002-07-04 Biowindow Gene Development Inc. Shanghai A novel polypeptide-corticotropin releasing factor 8.8 and the polynucleotide encoding said polypeptide
WO2002067996A2 (en) * 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Beta-endorphin/crf gene therapy for locally combating pain
WO2003004049A2 (en) * 2001-07-02 2003-01-16 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2006021814A2 (en) * 2004-07-08 2006-03-02 Aimsco Limited Medicament
WO2006117573A1 (en) * 2005-05-04 2006-11-09 Aimsco Limited Combination therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADDO E ET AL: "ACTH--inosine pranobex in the treatment of AIDS. Encouraging results.", THE WEST INDIAN MEDICAL JOURNAL SEP 1989, vol. 38, no. 3, September 1989 (1989-09-01), pages 142 - 147, XP008081944, ISSN: 0043-3144 *
BARCELLINI W ET AL: "Alpha-melanocyte-stimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes.", JOURNAL OF LEUKOCYTE BIOLOGY NOV 2000, vol. 68, no. 5, November 2000 (2000-11-01), pages 693 - 699, XP002444926, ISSN: 0741-5400 *
CATANIA A ET AL: "Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients.", PEPTIDES 1998, vol. 19, no. 6, 1998, pages 1099 - 1104, XP002444925, ISSN: 0196-9781 *
CATANIA A ET AL: "Proopiomelanocortin-derived peptides and cytokines: relations in patients with acquired immunodeficiency syndrome.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY JAN 1993, vol. 66, no. 1, January 1993 (1993-01-01), pages 73 - 79, XP002444924, ISSN: 0090-1229 *
CATANIA ANNA ET AL: "Targeting melanocortin receptors as a novel strategy to control inflammation.", PHARMACOLOGICAL REVIEWS MAR 2004, vol. 56, no. 1, March 2004 (2004-03-01), pages 1 - 29, XP002444946, ISSN: 0031-6997 *
DATABASE WPI Week 200145, Derwent World Patents Index; AN 2001-425635, XP002444734 *
DATABASE WPI Week 200253, Derwent World Patents Index; AN 2002-500761, XP002444733 *
GHAFOURI ET AL.: "HIV-I associated dementia: symptoms and causes", RETROVIROLOGY, vol. 3, no. 28, 19 May 2006 (2006-05-19), pages 1 - 11, XP002442845 *

Also Published As

Publication number Publication date
CN101394862A (en) 2009-03-25
IL192618A0 (en) 2009-02-11
EA015924B1 (en) 2011-12-30
AU2007203991A1 (en) 2007-07-12
KR20080098488A (en) 2008-11-10
US20120208745A1 (en) 2012-08-16
ZA200806505B (en) 2009-05-27
BRPI0706311A2 (en) 2011-03-22
WO2007077465A2 (en) 2007-07-12
AP2913A (en) 2014-05-31
MX2008008768A (en) 2008-09-11
US20140072530A1 (en) 2014-03-13
CA2635562A1 (en) 2007-07-12
US20090291060A1 (en) 2009-11-26
KR20140114443A (en) 2014-09-26
EA200870158A1 (en) 2008-12-30
IL192618A (en) 2012-06-28
EP1968624A2 (en) 2008-09-17
AU2007203991B2 (en) 2013-01-17
AP2008004560A0 (en) 2008-08-31
JP5180095B2 (en) 2013-04-10
JP2009522345A (en) 2009-06-11
GB0600202D0 (en) 2006-02-15
NZ569604A (en) 2011-01-28
US20130210710A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
WO2007077465A3 (en) Treatment of hiv
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2008003149A3 (en) Substituted pteridines for the treatment and prevention of viral infections
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2007081974A3 (en) Viral hepatitis treatment
WO2007126824A3 (en) Methods and systems for sterilization
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2006128121A3 (en) Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2008005705A3 (en) Metal-containing formulations and methods of use
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2007125105A3 (en) Benzamide glucokinase activators
WO2007059202A3 (en) Pyrazolyl urea derivatives useful in the treatment of cancer
WO2009135048A3 (en) Highly pure plasmid dna preparations and processes for preparing the same
WO2007022385A3 (en) Use of cxcr4 binding molecules for the treatment of whim syndrome
WO2006081203A3 (en) Composites and methods for the manufacture and use thereof
WO2009156182A3 (en) Uracil derivatives and use thereof
WO2011049914A3 (en) Anti-hiv peptides and methods of use thereof
WO2009093007A3 (en) Immune modulation by regioselectively modified glycosides
EA201200934A1 (en) ANTI-TRACT COMBINATIONS OF MEDICINES BASED ON ARTHEMISININE WITH OTHER CHEMOTHERAPEUTIC AGENTS
WO2007021852A3 (en) Transplatinum complexes with n2o2 donor sets as cytotoxic and antitumor agents
WO2008042841A3 (en) Docetaxel compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 192618

Country of ref document: IL

Ref document number: 2007203991

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2635562

Country of ref document: CA

Ref document number: MX/a/2008/008768

Country of ref document: MX

Ref document number: 2008549065

Country of ref document: JP

Ref document number: 569604

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12008501612

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007700413

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007203991

Country of ref document: AU

Date of ref document: 20070105

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2007203991

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2008/004560

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 1020087019225

Country of ref document: KR

Ref document number: 200870158

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200780007742.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2007700413

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12087442

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0706311

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080704